CLINICAL_TRIALS ClinicalTrials.gov record with results posted

A Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With the Sodium-glucose Transport Protein 2 (SGLT2) Inhibitor EmpaGliflozin in patiEnts With Non-alcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05232071
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-09-10T00:04:56.021551+00:00
Published At: 2026-09-09T00:00:00+00:00
Record Updated At: 2026-09-09
Results Posted At: 2026-09-09
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["NASH - Nonalcoholic Steatohepatitis", "Diabetes Mellitus, Type 2"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-09-09"
protocolSection.identificationModule.nctId: "NCT05232071"
protocolSection.identificationModule.officialTitle: "A Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With the Sodium-glucose Transport Protein 2 (SGLT2) Inhibitor EmpaGliflozin in patiEnts With Non-alcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2026-09-09"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.